iRadimed Corporation $IRMD Shares Acquired by Lazard Asset Management LLC

Posted by Geri Gentry on Aug 1st, 2026

Lazard Asset Management LLC increased its position in shares of iRadimed Corporation (NASDAQ:IRMD – Free Report) by 15.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,914 shares of the medical equipment provider’s stock after buying an additional 6,524 shares during the period. Lazard Asset Management LLC’s holdings in iRadimed were worth $4,708,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Aristides Capital LLC grew its stake in shares of iRadimed by 8.5% during the first quarter. Aristides Capital LLC now owns 30,083 shares of the medical equipment provider’s stock valued at $2,896,000 after acquiring an additional 2,349 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in iRadimed by 144.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 15,445 shares of the medical equipment provider’s stock valued at $1,487,000 after purchasing an additional 9,136 shares during the last quarter. Sei Investments Co. grew its stake in iRadimed by 17.2% during the 1st quarter. Sei Investments Co. now owns 74,304 shares of the medical equipment provider’s stock valued at $7,153,000 after purchasing an additional 10,908 shares in the last quarter. State of Wyoming increased its holdings in iRadimed by 194.5% during the 1st quarter. State of Wyoming now owns 2,748 shares of the medical equipment provider’s stock worth $265,000 after purchasing an additional 1,815 shares during the last quarter. Finally, First Trust Advisors LP purchased a new stake in iRadimed during the 1st quarter worth approximately $225,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Stock Performance

Shares of NASDAQ:IRMD opened at $90.86 on Friday. The company’s fifty day moving average is $94.54 and its two-hundred day moving average is $95.70. iRadimed Corporation has a 1-year low of $57.83 and a 1-year high of $107.90. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of 49.65 and a beta of 0.90.

iRadimed (NASDAQ:IRMD – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The business had revenue of $20.47 million during the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Sell-side analysts expect that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Investors of record on Friday, August 14th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is 43.72%.

Key Stories Impacting iRadimed

Here are the key news stories impacting iRadimed this week:

Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $120.00.

Read Our Latest Report on IRMD

Insider Transactions at iRadimed

In other news, CEO Roger E. Susi sold 2,500 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the transaction, the chief executive officer owned 2,162,500 shares of the company’s stock, valued at approximately $195,922,500. The trade was a 0.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 21,250 shares of company stock valued at $1,836,403 in the last quarter. Company insiders own 34.60% of the company’s stock.

iRadimed Company Profile

(Free Report)

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.